Literature DB >> 23001412

HIV-negative and HIV-positive gay men's attitudes to medicines, HIV treatments and antiretroviral-based prevention.

Martin Holt1, Dean Murphy, Denton Callander, Jeanne Ellard, Marsha Rosengarten, Susan Kippax, John de Wit.   

Abstract

We assessed attitudes to medicines, HIV treatments and antiretroviral-based prevention in a national, online survey of 1,041 Australian gay men (88.3% HIV-negative and 11.7% HIV-positive). Multivariate analysis of variance was used to identify the effect of HIV status on attitudes. HIV-negative men disagreed with the idea that HIV drugs should be restricted to HIV-positive people. HIV-positive men agreed and HIV-negative men disagreed that taking HIV treatments was straightforward and HIV-negative men were more sceptical about whether HIV treatment or an undetectable viral load prevented HIV transmission. HIV-negative and HIV-positive men had similar attitudes to pre-exposure prophylaxis but divergent views about 'treatment as prevention'.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23001412     DOI: 10.1007/s10461-012-0313-z

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  13 in total

1.  Antiretroviral chemoprophylaxis: state of evidence and the research agenda.

Authors:  Kenneth H Mayer
Journal:  Clin Infect Dis       Date:  2014-07       Impact factor: 9.079

2.  Gay Men's Understanding and Education of New HIV Prevention Technologies in Vancouver, Canada.

Authors:  Benjamin J Klassen; Nathan J Lachowsky; Sally Yue Lin; Joshua B Edward; Sarah A Chown; Robert S Hogg; David M Moore; Eric A Roth
Journal:  Qual Health Res       Date:  2017-07-01

3.  'Not Until I'm Absolutely Half-Dead and Have To:' Accounting for Non-Use of Antiretroviral Therapy in Semi-Structured Interviews with People Living with HIV in Australia.

Authors:  Christy E Newman; Limin Mao; Asha Persson; Martin Holt; Sean Slavin; Michael R Kidd; Jeffrey J Post; Edwina Wright; John de Wit
Journal:  AIDS Patient Care STDS       Date:  2015-03-25       Impact factor: 5.078

4.  Belief in Treatment as Prevention and Its Relationship to HIV Status and Behavioral Risk.

Authors:  Kiffer G Card; Heather L Armstrong; Nathan J Lachowsky; Zishan Cui; Paul Sereda; Allison Carter; Julio S G Montaner; Robert S Hogg; Eric A Roth; David M Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2018-01-01       Impact factor: 3.731

5.  Australian gay and bisexual men's attitudes to HIV treatment as prevention in repeated, national surveys, 2011-2013.

Authors:  Martin Holt; Toby Lea; Dean A Murphy; Jeanne Ellard; Marsha Rosengarten; Susan C Kippax; John B F De Wit
Journal:  PLoS One       Date:  2014-11-11       Impact factor: 3.240

6.  Key factors in the acceptability of treatment as prevention (TasP) in Scotland: a qualitative study with communities affected by HIV.

Authors:  I Young; P Flowers; L M McDaid
Journal:  Sex Transm Infect       Date:  2014-12-07       Impact factor: 3.519

Review 7.  How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention.

Authors:  Ingrid Young; Lisa McDaid
Journal:  AIDS Behav       Date:  2014-02

8.  Implementation challenges and opportunities for HIV Treatment as Prevention (TasP) among young men in Vancouver, Canada: a qualitative study.

Authors:  Rod Knight; Will Small; Kim Thomson; Mark Gilbert; Jean Shoveller
Journal:  BMC Public Health       Date:  2016-03-15       Impact factor: 3.295

9.  PEP and TasP Awareness among Italian MSM, PLWHA, and High-Risk Heterosexuals and Demographic, Behavioral, and Social Correlates.

Authors:  Gabriele Prati; Bruna Zani; Luca Pietrantoni; Diego Scudiero; Patrizia Perone; Lella Cosmaro; Alessandra Cerioli; Massimo Oldrini
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

10.  Willingness to Act upon Beliefs about 'Treatment as Prevention' among Australian Gay and Bisexual Men.

Authors:  Benjamin R Bavinton; Martin Holt; Andrew E Grulich; Graham Brown; Iryna B Zablotska; Garrett P Prestage
Journal:  PLoS One       Date:  2016-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.